[go: up one dir, main page]

AU2003276564A1 - Dual assay for evaluating activity and cytotoxicity of compounds in the same - Google Patents

Dual assay for evaluating activity and cytotoxicity of compounds in the same

Info

Publication number
AU2003276564A1
AU2003276564A1 AU2003276564A AU2003276564A AU2003276564A1 AU 2003276564 A1 AU2003276564 A1 AU 2003276564A1 AU 2003276564 A AU2003276564 A AU 2003276564A AU 2003276564 A AU2003276564 A AU 2003276564A AU 2003276564 A1 AU2003276564 A1 AU 2003276564A1
Authority
AU
Australia
Prior art keywords
cytotoxicity
compounds
same
evaluating activity
dual assay
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003276564A
Inventor
Wade Stanton Blair
Joan Qun Cao
Jason Steven Isaacson
Amy Karen Patick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Corp SRL
Original Assignee
Pfizer Corp Belgium
Pfizer Corp SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Corp Belgium, Pfizer Corp SRL filed Critical Pfizer Corp Belgium
Publication of AU2003276564A1 publication Critical patent/AU2003276564A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G01N33/5017—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity for testing neoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2003276564A 2002-11-25 2003-11-13 Dual assay for evaluating activity and cytotoxicity of compounds in the same Abandoned AU2003276564A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42938202P 2002-11-25 2002-11-25
US60/429,382 2002-11-25
PCT/IB2003/005182 WO2004048613A2 (en) 2002-11-25 2003-11-13 Dual assay for evaluating activity and cytotoxicity of compounds in the same

Publications (1)

Publication Number Publication Date
AU2003276564A1 true AU2003276564A1 (en) 2004-06-18

Family

ID=32393555

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003276564A Abandoned AU2003276564A1 (en) 2002-11-25 2003-11-13 Dual assay for evaluating activity and cytotoxicity of compounds in the same

Country Status (2)

Country Link
AU (1) AU2003276564A1 (en)
WO (1) WO2004048613A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040209246A1 (en) * 2003-04-15 2004-10-21 Agouron Pharmaceuticals, Inc. Dual reporter/dye reduction methodology for evaluating antiviral and cytotoxicity of hepatitis C virus inhibitors
WO2024193443A1 (en) * 2023-03-17 2024-09-26 高雄医学大学 Cell having reporter gene system of dual-structure chromogenic enzyme and use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5292658A (en) * 1989-12-29 1994-03-08 University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center Cloning and expressions of Renilla luciferase
AUPM890694A0 (en) * 1994-10-19 1994-11-10 Institute For Child Health Research Cytoassay
US6007998A (en) * 1996-04-22 1999-12-28 Merck & Co., Inc. Leptin assay
CA2427472A1 (en) * 2000-10-27 2002-06-06 Tae Kook Kim Double and triple readout assay systems

Also Published As

Publication number Publication date
WO2004048613A3 (en) 2004-08-12
WO2004048613A2 (en) 2004-06-10

Similar Documents

Publication Publication Date Title
AU2003257666A1 (en) COMPOUND HAVING TGFss INHIBITORY ACTIVITY AND MEDICINAL COMPOSITION CONTAINING THE SAME
AU2003243736A1 (en) Improved assay systems and components
AU2003209060A1 (en) Assay for acytyltransferase or deacetylase activity
AU2003241327A1 (en) Amidinylphenyl compounds and their use as fungicides
IL166129A0 (en) Pyrrolotriazine derivatives and pharmaceutical compositions containing the same
AU2003257668A1 (en) Fastener and fitted body having the fastener
AU2003295551A1 (en) Wiping articles and their use
AU2002364051A1 (en) Anti-cancer combination and use thereof
AU2003290685A1 (en) Active fasteners
AU2003239610A1 (en) Tiled biochips and the methods of making the same
AU2003264059A1 (en) Cleaning composition and cleaning of vehicles
AU2003290722A1 (en) Methods and compositions for detecting telomerase activity
AU2003274351A1 (en) Substituted pyridyloxyalkylamides and their use as fungicides
AU2003289228A1 (en) Material for fuel-system part and fuel-system part comprising the same
AU2003290663A1 (en) Assay for tissue factor and factor viia
AU2002316577A1 (en) Cell-screening assay and composition
AU2003231827A1 (en) Pseudo-tissues and uses thereof
AU2003262744A1 (en) Alpha-AMYLASE ASSAY AND USES THEREOF
EP1585971A3 (en) a-AMYLASE ASSAY AND USES THEREOF
AU2003276564A1 (en) Dual assay for evaluating activity and cytotoxicity of compounds in the same
AU2003284597A1 (en) Apoptosis-associated protein and use thereof
AU2003288924A1 (en) Diagnostic assay and related products
AU2003302173A1 (en) Spirotetrathiocarbamates and spirooxothiocarbamates
AU2003228305A1 (en) Pharmaceutical composition with combined active agents and methods for using the same
AU2003228397A1 (en) HAUSP-p53 INTERACTION AND USES THEREOF

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase